key: cord-0976419-y4gieyj2
authors: De, Priyasha; Chakraborty, Ishita; Karna, Bhargavi; Mazumder, Nirmal
title: Brief review on repurposed drugs and vaccines for possible treatment of COVID-19
date: 2021-02-25
journal: Eur J Pharmacol
DOI: 10.1016/j.ejphar.2021.173977
sha: 35fa6d2294e66a184201d62b6a490442287d9f0c
doc_id: 976419
cord_uid: y4gieyj2

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of the pandemic coronavirus disease 2019 (Covid-19) has claimed more than a million lives. Various in silico, in vitro, and in vivo studies are being conducted to understand the effect of SARS-CoV-2 on the cellular metabolism of humans and the various drugs and drug-targets that may be used. In this review, we discuss protein-protein interactions (PPIs) between viral and human proteins as well as viral targets like proteases. We try to understand the molecular mechanism of various repurposed antiviral drugs against SARS-CoV-2, their combination therapies, drug dosage regimens, and their adverse effects along with possible alternatives like non-toxic antiviral phytochemicals. Ultimately, randomized controlled trials are needed to identify which of these compounds has the required balance of efficacy and safety.

Coronaviruses belong to the family Coronaviridae which in turn consists of two subfamilies Torovirinae and Coronavirinae. The International Committee of Taxonomy of Viruses (ICTV) classifies the Coronavirinae subfamily into four main genera -alpha, beta, gamma, and delta.

The severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) along with some other human coronaviruses like Human coronavirus-Hong Kong university 1 (HCoV-HKU1) and HCoV-OC43, belong to the class of beta coronaviruses which are believed to infect only mammals (Pillaiyar et al., 2020) . Several epidemics have emerged in the past due to these coronaviruses. SARS-CoV evolved around [2000] [2001] [2002] [2003] [2004] in Guangdong, China and bats were the intermediate hosts. Then, the MERS-CoV emerged in Saudi Arabia in 2012 and infected dromedary camels were responsible for infecting humans directly or indirectly (Kandeel and Al-Nawazi, 2020; Mckee et al., 2020 ; available at who.int) . In December 2019, the coronavirus which apparently emerged from the Hunan seafood market in Wuhan, China and rapidly infected more than 50 people, was first named 2019 novel coronavirus (2019-nCoV). It was then suggested that it was a novel betacoronavirus of effect of viral NSPs and ORFs on human cellular metabolism (Gordon a et al., 2020) . Interaction of viral spike protein (S) with human acyl-transferase complex GOLGA7-ZDHHC5 leads to palmitoylation of the cytosolic tail which facilitates fusion of the viral and host cell membranes (Gordon a et al., 2020; Knoops et al., 2008) . Host proteins interact with viral NSP8 coding for the signal recognition particle, ORF8 for endoplasmic reticulum (ER) quality control, M for the morphology of ER, and NSP13 for golgins, which help in the reconfiguration of Golgi/ER trafficking during infection with coronavirus. Modifications of endomembrane compartments by NSP6, NSP7, NSP10, and ORF3a help in the replication of coronavirus (Gordon et al., 2020) .

Interaction of NSP8 and signal recognition particle suggests viral hijacking of the Sec61 translocon which helps to insert SARS-CoV-2 proteins into the host ER membrane (Gordon et al., 2020; Knoops et al., 2008) . Sigma receptors in the host interact with viral NSP6 and ORF9c to regulate ER stress response and lipid remodeling; thus, help in viral replication (Gordon et al., 2020; Hellewell et al., 1994; Mitsuda et al., 2011) . NSP5 inhibits the transport of histone deacetylase 2 (HDAC2) into the human cell nucleus by cleaving the epigenetic regulator between the nuclear localization sequence and the HDAC domain thus, HDAC2 cannot mediate inflammation and interferon response (Gordon a et al., 2020; Barnes 2009; Xu et al., 2019) . Viral NSP5 also reacts with human tRNA methyltransferase 1 (TRMT1) leading to dimethylguanosine base modification on the tRNA of both nucleus and mitochondrian (Gordon a et al., 2020) . NSP5

The PPIs between SARS-CoV-2 and human proteins as well as other molecular targets can be targeted by various repurposed drugs (Fig. 3A) . Cheminformatic literature search and specialist knowledge revealed 69 drugs, some of which are approved and some clinical and preclinical candidates from other research, with the potential to target the interacting viral and host proteins ( Fig. 3B -C) (Gordon a et al., 2020; Gordon et al., 2020) . The CoVex software can also be used to map the SARS-CoV-2 and human PPIs and identify repurposable drugs (Fig. 3) (Sadegh et al., 2020) . These drugs include bafilomycin A1 which inhibits V1-ATPase responsible for inhibiting autophagy and transport of endosomes. Its subunits react with the viral NSP6 and M impacting the viral life cycle. Some drugs target the epigenetic regulators in the host like valproic acid, which is an approved drug, and apicidin, a preclinical candidate, that inhibit HDAC2. Clinical candidates like ABBV-744 and CPI-0610 inhibit BRD2/4 (Gordon a et al., 2020) . Similarly, a natural product like WDB002, obtained from a soil-inhabiting Streptomyces bacterium, is known to first target a human protein called FKBP12, further forming a complex with the human centrosomal protein, CEP250, which interacts with viral NSP13 (Shigdel et al., 2020) . Likewise, mycophenolic acid, ribavirin, and merimepodib seem to play a role in inhibiting inosine-5'monophosphate dehydrogenase 2 (IMPDH2) which interacts with viral NSP14 for the biosynthesis of human purine in viral replication. Sapanisertib and rapamycin are inhibitors of the mTORC1 pathway, repressing the mTOR translation in viral synthesis and replication (Gordon a et al., 2020) . Silmitasertib, particularly, reduces stress granule disassembly by CK2 inhibition thus increasing stress granules required for innate immune response in viral replication (Table 1) (Gordon a et al., 2020; Reineke et al., 2017) . Another small molecule drug is pevonedistat that can be used to inhibit the NEDD8-activating enzyme (NAE) that helps in the neddylation of Cullin 2 (CUL2) required for ubiquitin transfer to the substrate; thus, hijacking J o u r n a l P r e -p r o o f the ubiquitination pathway and helping in the replication of the virus (Gordon a et al., 2020; Soucy et al., 2009) . Antibiotics like chloramphenicol, tigecycline, and linezolid also have an offtarget effect against host mitochondrial ribosomes which react with viral protein NSP8 (Gordon a et al., 2020; Mckee et al., 2006) .

These 69 ligands were then investigated for antiviral activity against SARS-CoV-2 infected Vero E6 cells by cell viability, plaque-forming, and off-target assays. Two main types of antiviral molecules against SARS-CoV-2 were found, molecules binding to sigma-1 and sigma-2 receptors, and protein biogenesis inhibitors (Gordon et al., 2020) . It was also found that RNA helicase, eukaryotic initiation factor-4A (eIF4A) inhibitor, zotatifin as well as the eukaryotic translation elongation factor-1A (eEF1A) inhibitor, ternatin-4, help to reduce the rate of mRNA translation in SARS-CoV-2. PS3061, a Sec61 inhibitor, blocks SARS-CoV-2 replication by inhibiting SARS-CoV-2 protein insertion into the ER (Gordon et al., 2020; Carelli et al., 2015) Drugs that show antiviral activity by acting as ligands of the sigma receptor include haloperidol, chloroquine, clemastine, cloperastine, progesterone, and astemizole (Gordon a et al., 2020; Gordon et al., 2020; Hellwell et al., 1994) . It was shown that sigma-1 receptor agonist, dextromethorphan exhibits proviral activity against SARS-CoV-2, and ligands like PB28 have high selectivity against off-target proteins like hERG ion channels but very high efficacy for sigma receptors. PB28 has also shown higher antiviral activity than hydroxychloroquine (Table

Studies summarise the various virus-based anti-CoV therapeutics that can be developed by understanding the genomics and targeting specific viral enzymes and host receptors of various coronaviruses like SARS-CoV. This can give an insight into new SARS-CoV-2 targets apart from the PPIs between the virus and the host due to the 79.5% genetic similarity between SARS-CoV and SARS-CoV-2 (Pillaiyar et al., 2020; Rabi et al., 2020) . RNA helicase eIF4A inhibitor, silvestrol, a non-toxic inhibitor of viral mRNA translation, helps to inhibit the structural and nonstructural protein expression as well as viral replicase/transcriptase complex formation in CoVs (Pillaiyar et al., 2020; Müller et al., 2018) . PL pro is an important target for antiviral therapy in coronaviruses including SARS-CoV-2 because it is involved in deubiquitination and innate immune response evasion by the virus in addition to its proteolytic activity (Mielech et al., 2014) . Various SARS-CoV PL pro inhibitors identified are thiopurine compounds, zinc ion as well as naphthalene inhibitors (Báez-Santos et al., 2015) . 8-(Trifluoromethyl)-9H-purin-6-amine, as well as benzotriazole and B. papyrifera derivatives can inhibit both 3CL pro and PL pro CoV proteases (Park et al., 2017) . Non-peptide inhibitors of SARS-CoV 3CL pro include decahydroisoquinoline (Shimamoto et al., 2015) . SK40 with isoserine backbone can be used against the mutant protease, R188I, in SARS-CoV where the mature SARS-CoV 3CL pro undergoes degradation (Konno et al., 2017) . SSYA10-001 is a small 1,2,4-triazole derivative that can inhibit NSP13 or the viral helicase of SARS-CoV, and thus not allow its replication (Adedeji et al., 2014) . The host innate interferon response is important for controlling viral replication. Cinatl et al., 2003) . Rapamycin, trametinib, everolimus, imatinib, selumetinib, and dasatinib block the ABL1 and AKT-mTOR pathways which help to block viral entry and post-entry events in J o u r n a l P r e -p r o o f SARS-CoVs (Kindrachuk et al., 2015) . N-(2-aminoethyl)-1-aziridineethanamine can inhibit cellcell fusion as well as ACE2 catalytic activity (Huentelman et al., 2004) . Small molecules like SSAA09E2, discovered for blocking viral entry, blocked the interaction between viral S protein and ACE2. SSAA09E1 blocked cathepsin L and SSAA09E3 prevented the fusion of host cellular membrane and viral membrane (Adedeji et al., 2013) . Hexamethylene amiloride is a viroporin inhibitor that reduces the activity of the E ion channels in SARS-CoV (Wilson et al., 2006) .

Apart from virus-based anti-CoV therapeutics, various repositioned drugs inhibiting the entry and replication of various coronaviruses that can also be used against SARS-CoV-2 are summarised in different research studies (Pillaiyar et al., 2020) . Seven broad-spectrum inhibitors with low 50% effective concentration (EC 50 ) values: emetine, lycorine, phenazopyridine, mycophenolate mofetil, pyrvinium pamoate, monensin sodium, and mycophenolic acid, suppressed replication of various coronaviruses in a dose-dependent manner (Shen et al., 2019) .

The antipsychotic drug, chlorpromazine, can inhibit the clathrin-mediated endocytosis of the virus. Similarly, loperamide helps to reduce intestinal motility but it can also inhibit CoV replication (Pillaiyar et al., 2020; De Wilde et al., 2014) . A combination therapy of two anticancer drugs, saracatinib, which inhibits Src-family of tyrosine kinases (SFKs), screened using Huh-7 cells, and gemcitabine can help to treat CoV diseases (Pillaiyar et al., 2020) . E-64-D inhibits cathepsin which is required for the fusion step during the viral entry (Yang et al., 2004) .

Dasatinib and imatinib mesylate are known to inhibit the ABL-1 pathway which is important for viral replication. Likewise, DNA synthesis inhibitors like toremifene citrate and gemcitabine hydrochloride can also be used in antiviral therapy against coronavirus (Pillaiyar et al., 2020) .

All these drugs and small molecules inhibiting the replication of different coronaviruses can J o u r n a l P r e -p r o o f potentially be used against SARS-CoV-2. These repurposed drugs and their combination therapies might prove to be very beneficial for Covid-19 treatment.

Apart from summarising the repurposed drugs, some studies conducted in vitro assays to find out the drug action mechanism of the repurposed drug ( Table 1 ). The mechanism of action of chloroquine against SARS-CoV-2 is predicted to be the same as it is for SARS-CoV. Viral antigens were visualized in SARS-CoV-infected Vero E6 cells by indirect immunofluorescence and it was suggested that chloroquine can have both prophylactic and therapeutic advantages: it could prevent viral infection in-vitro when it was added 24 h before viral infection and was effective when added 3-5 h post-infection as well. Immunoprecipitation analyses showed that cellular trafficking, N-glycosylation, and other enzymatic processes are regulated by the low acidic pH of the vesicles. Chloroquine increases the pH of the endocytic vesicles, thus it affects viral entry. Chloroquine reduces the biosynthesis of the viral spike protein by reducing the level of Golgi-modified pro-spike leading to a reduction in viral replication (Vincent et al., 2005) . NH 4 Cl can reduce the transduction of viruses with SARS-CoV spike protein and affect the terminal modifications of the N-glycosylated chains of ACE2 which leads to less efficient ACE2-SARS-CoV interaction (Yang et al., 2004) . Protein expression of under-glycosylated ACE2 on the surface of the cell and its poor affinity to viral spike proteins may be the primary mechanism for the prevention of viral infection by pre-treatment of drugs. Elevation of pH in endosomes affecting the virus-endosome fusion may be the mechanism for treatment with chloroquine after viral infection (Vincent et al, 2005) .

Studies suggest that chloroquine can be used to study interactions of nanoparticles like a virus with the host cells to obtain information about the changes induced by chloroquine on cellular uptake of SARS-CoV-2 (Hu and Wolfram, 2020) . SARS-CoV-2 shape (spherical) and size (60-140 nm) are within the same range as most other synthetic nanoparticles (Zhu et al., 2020) . Chloroquine reduces the accumulation of nanoparticles like a virus in macrophages as well as expression of cargo-selecting clathrin adaptor, phosphatidylinositol binding clathrin assembly protein which affects membrane curvature leading to inhibition of endocytosis of SARS-CoV-2 viral nanoparticle into the host cell (Wolfram et al., 2017; Miller et al., 2015) .

Prevention of lysosome acidification by chloroquine leads to interference in the fusion of endocytic vesicles and membrane receptor recycling which is necessary for cellular entry of SARS-CoV-2 (Hu and Wolfram, 2020; Haladyj et al., 2018) . It also inhibits the fusion of viral envelope with the endosome because of the inactivated viral surface spike protein which is required to be activated for the fusion. The activation of spike protein is done by endosomal proteases like cathepsins which are activated only by the acidification of endosomes and chloroquine is known to inhibit this acidification (Hu and Wolfram, 2020) .

Hydroxychloroquine is another repurposed drug for Covid-19 which is found to be less toxic than chloroquine for inhibition of SARS-CoV-2 infection in vitro (Vero E6 cells) . Hydroxychloroquine can reduce the inflammatory response and cytokine storm (aggressive inflammatory response with the release of a large amount of proinflammatory cytokines) in patients severely infected with SARS-CoV-2 by blocking T-cell stimulation, and thus decreasing cytokine production. It can also disrupt the interaction between DNA/RNA and the toll-like receptors to inhibit the expression of pro-inflammatory genes Zhou et al., 2020) . In a study, a cytotoxicity assay was conducted on Vero E6 cells to J o u r n a l P r e -p r o o f find the 50% cytotoxic concentration (CC 50 ) as well as dose-response curves to find EC 50 for chloroquine and hydroxychloroquine. Immunofluorescence revealed that cells treated with chloroquine and hydroxychloroquine had more virions with early endosome antigen 1 (EEA1) EEs, and very few were co-localized with late endosomal-lysosomal protein LAMP1 + ELs. In untreated cells, ELs were higher than EEs (Liu et al., 2020). Thus, they concluded that transport of SARS-CoV-2 from EEs to ELs, required for the release of the viral genome for replication is blocked by chloroquine and hydroxychloroquine (Mingo et al., 2015) . This also changed their morphology, abnormally increasing the size of EEs. It can be said that the failure of transport of virions to the final releasing site is due to inhibition of endosomal maturation by pH elevation caused due to chloroquine and hydroxychloroquine .

Apart from chloroquine, arbidol (umifenovir) can also be used to treat prophylactically. It interferes with clathrin-mediated endocytosis and interacts with viral glycoprotein aromatic residues which are required for cellular recognition and fusion of the virus (Teissier et al., 2011; Kadam and Wilson 2017) . A combination therapy of darunavir, which is a viral protease inhibitor, and cobicistat, which enhances pharmacokinetics of darunavir by inhibiting cytochrome P450, can be used to treat Covid-19 (Available at Clinicaltrials.gov; Santos et al., 2019) . Initially, Vero E6 cells were used to test favipiravir which is a Covid-19 experimental drug used against the Ebola virus previously. Favipiravir inhibits viral RdRp just like the nucleotide analog prodrug, remdesivir (Oestereich et al., 2014; Wang et al., 2020) . These repurposed drugs screened by various in silico and in vitro antiviral screening systems have paved a path towards combating Covid-19.

The effects of combination therapies are required to be tested in Covid-19 patients (Available at who.int). Some antiviral drugs for Covid-19 patients were supplemented with interferons, which are signaling proteins released in response to viral infection by the host cell; corticosteroids, that help to reduce inflammation; and other repurposable approved drugs to increase their efficiency which would lead to higher survival rates of the patients (Table 1) . However, the ability of corticosteroids to suppress the innate host defense against the virus must be considered.

Therefore, clinical trials were conducted for these combination therapies. Viral protease inhibitors like ritonavir and lopinavir, were known to help increase ribavirin efficiency. (Chu et al., 2004) . Similarly, combination therapy of corticosteroid and interferon-α-1 improved the saturation of oxygen (Loutfy et al., 2003) . Corticosteroid therapy in Covid-19 patients has the potential to show higher survival rates by suppressing the cytokine storm of interferons, interleukins (IL) and tumor necrosis factor (TNF) caused in response to acute viral respiratory infections which lead to tissue injury . Early administration of the corticosteroid, dexamethasone, in patients with moderate-to-severe ARDS, could reduce the lung-protective mechanical ventilation duration and overall mortality (Villar et al., 2020) . SARS-CoV-2 infected patients also experience ARDS. Studies suggest that corticosteroids can attenuate the systemic and pulmonary damage in ARDS patients due to their antifibrotic and antiinflammatory properties (Rhen and Cidlowski, 2005) . Corticosteroids improved the PaO2/FiO2 (Ratio between oxygen partial pressure in arterial blood and inspired oxygen fraction) above 200 mm Hg within 24 h. Dexamethasone increased the survival of patients treated with extracorporeal lung support. Patients treated with dexamethasone experienced lower Sequential Organ Failure Assessment score from day 3 of treatment initiation. Consequently, dexamethasone increased the number of ventilator-free days by more than 4 days and increased J o u r n a l P r e -p r o o f the 60-day survival for ARDS patients by 15%. The number of ICU deaths due to multiple organ failure in dexamethasone-treated patients decreased by almost half compared to the control group (Villar et al., 2020) . An editorial also focused on the cytokine storm of TNF-α, IL-6, and IL-12 in the case of Covid-19 and its role in acute lung injury (ALI) and also the ability of one cytokine to induce other cytokines for increasing the pro-inflammatory response as seen in the case of TNF-α inducing IL-6 levels. Cytokine storm is also complemented with the generation of anaphylatoxins like C3a and C5a which induce innate immune cells to release the proinflammatory cytokines. Oncologists have used monoclonal antibodies (mAbs) to interrupt cytokine storm in cancer treatment. Thus, IL-6 inhibition with the anti-IL-6R mAb (tocilizumab) is predicted to enhance the treatment of Covid-19 as it helps to reduce C5aR1 and C5aR2 in blood along with a decrease in C-reactive protein (Buonaguro et al., 2020) .

In another study, supplementing azithromycin along with hydroxychloroquine in Covid-19 patients, helped to clear the virus more efficiently, leading to a rapid decline in the viral load in the nasopharynx (Gautret et al., 2020) . Azithromycin also decreases mucus secretion and increases the function of the lungs by acting directly on bronchial epithelial cells (Gielen et al., 2010) . Furthermore, it targets granulocytes, it blocks viral endocytosis by accumulating in lysosomes and thus, affecting adhesion and apoptosis of neutrophils (Tyteca et al., 2002; Oliver and Hinks et al.m 2020) . It can also inhibit vacuolar ATPase required for lysosomeautophagosome fusion, by inhibiting autophagy. Azithromycin also exhibits anti-inflammatory properties via suppression of IL1-beta, IL2, and TNF thus, it helps to deal with the aggravated immune response in the case of Covid-19. Azithromycin inhibits the T-cells via inhibition of NF-KB activation and calcineurin signaling. The immunomodulatory properties of azithromycin have shown effective response in various respiratory diseases like asthma and Chronic Obstructive J o u r n a l P r e -p r o o f Pulmonary Disease (Oliver and Hinks, 2020) . Clinical trials showed that these drugs screened in the Covid-19 patients helped to increase the efficiency of the other repurposed drugs in combination therapies, relieve the symptoms, and increase the survival rates of patients. These drugs screened by in silico, in vitro, and in vivo studies require to undergo large scale randomized controlled trials for testing efficacy and safety. . A study says that in patients with mild to severe form of Covid-19 pneumonia, with 500 mg of chloroquine two times a day, the therapeutic concentration could be reached . Earlier research done with hydroxychloroquine for long-term treatment revealed that a dose of 600 mg/day could help to reach a concentration of 1 μg/mL in the body (Lagier et al., 2014) . The optimum dose of hydroxychloroquine for SARS-CoV-2 still needs to be assessed which might include a loading dose followed by a maintenance one (Colson et al., 2020).

Various clinical trials for the dose optimization of chloroquine and hydroxychloroquine supplemented with other antivirals yielded a variety of results (Table 1) . A study summarised the J o u r n a l P r e -p r o o f dosage requirements of chloroquine and hydroxychloroquine which are cheap and easily available and have the potential to curb the global pandemic, Covid-19. Emergency use authorization was issued by the Food and Drug Administration (FDA) for the use of these two drugs to treat Covid-19. The study summarised that the seventh edition of the "Guidance of Coronavirus Disease 2019" of China recommended a chloroquine phosphate dosage of 500 mg twice a day for 7 days for patients aged between 18 and 65 with more than 50 kg of body weight, and for the ones less than 50 kg, a dosage of 500 mg two times a day for the first two days and then a single dose of 500 mg per day for the next 3-7 days (Gao and Hu 2020) . Chloroquine showed better results than lopinavir/ritonavir in decreasing the hospitalization duration of Covid-19 patients, bringing body temperature back to normal and conversion to virus-negative since the chloroquine-treated patients tested negative by day 7, 10, or 14 after treatment . Some adverse effects seen in these patients include nausea, diarrhea, rash, cough, and abdominal pain.

One of the studies revealed that a patient group receiving 200 mg hydroxychloroquine sulfate twice a day for 5 days along with the standard treatment of oxygen therapy, immunoglobulins, and other antivirals reduced the time taken by the body to return to normal temperature and decreased the cough remission time . Early administration of hydroxychloroquine in patients at the initial viral replication phase showed more benefit than the patients with the drug administered at the later hyperimmune response phase (Arshad et al., 2020) . Although treatment with hydroxychloroquine significantly reduced the viral load in Covid-19 patients, the addition of azithromycin to it showed more efficient results in virus elimination (Table 1 ). This was indicated in a study where patients were administered with 200 J o u r n a l P r e -p r o o f mg hydroxychloroquine sulfate 3 times a day for 10 days. Few of these hydroxychloroquinetreated patients received 500 mg of azithromycin on the first day and then 250 mg per day for the next 4 days to prevent superinfection by bacteria. Results at day 6 post inclusion showed that 57% of patients treated only with hydroxychloroquine were cured whereas 100% of the patients treated with the combination of azithromycin and hydroxychloroquine were cured. Results also showed that the effect of the drugs was higher in patients with respiratory tract infections symptoms like bronchitis, pneumonia, and pharyngitis than in asymptomatic patients. One of the patients treated only with hydroxychloroquine was PCR-positive for the virus even after the treatment; therefore, azithromycin was administered which cured the infection at the earliest (Gautret et al., 2020) . Another study did a multi-hospital assessment for this hypothesis. First, treatment only with hydroxychloroquine took place that involved 400 mg twice on day 1 followed by 200 mg twice a day from days 2-5 and 13.5% of people died in this group. Later, an only-azithromycin treatment followed which included administration of 500 mg once on day 1 and 250 mg once a day for the next 4 days where the mortality was 22.4%. The combination therapy of the two drugs was administered to the patients with very low cardiac risk factors which led to a 20% mortality. Additionally, O 2 saturation and Modified Sequential Organ Failure Assessment score were recorded which are important variables to predict disease severity and mortality. Results affirmed that hydroxychloroquine alone or in combination therapy with azithromycin led to higher survival of Covid-19 patients (Arshad et al., 2020).

Corticosteroid therapy in Covid-19 patients also showed higher survival rates. 20 mg dexamethasone once daily was administered to the patients from day 1-5 followed by 10 mg once a day from day 6-10 (Villar et al., 2020) . Corticosteroid therapy's main adverse effect is 

Various safety considerations need to be accounted for the use of azithromycin and hydroxychloroquine in the treatment or prophylaxis of Covid-19. A study reported the results of a few studies that the treatment of systemic lupus erythematosus using hydroxychloroquine led to QT interval prolongation and torsade de pointes provocation (Roden et al., 2020; Morgan et al., 2013) . Hydroxychloroquine is known to bind to the hERG protein important for the electrical activity regulation in the heart which in turn explains the cardiac side effects of hydroxychloroquine (Gordon et al., 2020) . Azithromycin is also known to cause severe retinopathy, arrhythmia, QT prolongation, higher risk for sudden death and to provoke polymorphic ventricular tachycardia. Risk groups for this include the females and older age groups (Gautret et al., 2020; Kim et al., 2005) . FDA Perspective also supported the results of some studies that proved that the administration of azithromycin makes the patient vulnerable to prolongation of QTc interval and torsade de pointes (Mosholder et al., 2013) . Various electrophysiologic studies suggested that the combinatorial effect of both hydroxychloroquine and azithromycin can provoke proarrhythmia . Very limited data is available J o u r n a l P r e -p r o o f about the safety of these combination therapies. Many randomized clinical trials to study their combined effect on QT or risk of arrhythmia are being initiated to find out more about the adverse drug reactions (Roden et al., 2020) .

Furthermore, various pharmacodynamic and pharmacokinetic models as well as in vitro studies were conducted to find out the effect of chloroquine and hydroxychloroquine on QTc prolongation to optimize the drug dosage for treatment of Covid-19. Another study predicted that higher doses of hydroxychloroquine (>400 mg twice a day) are more efficient in the reduction of transmissibility, viral suppression, and cure within 7 days. The effect of a low dose regimen could not be differentiated from that of a placebo (Garcia-Cremades et al., 2020) . The viral kinetic model of another study showed a 0.006 msec increase in QT interval due to a 1nM increase in chloroquine concentration that led to an increase in the rate of viral decline (Ursing et al., 2020) . Clinical Pharmacokinetics/Pharmacodynamics models showed a 50% viral load decline for plasma hydroxychloroquine concentrations estimated around 4 μM. The optimal dose for hydroxychloroquine should be below 7.5 μM as more than 1% of the patients experienced an increase in QTc interval by >60 msec. 800 mg hydroxychloroquine twice a day for 10 days has been known to be very efficient in decreasing the viral loads to 9% but is associated with significant QTc prolongation. Dosing regimens like 800 mg twice a day or 600 mg twice a day for 1-2 days followed by 400 mg twice a day or 200 mg thrice a day maintenance dose help in reaching the EC 50 levels faster and thus, prove to be more beneficial than extending treatment duration with lower doses (Garcia-Cremades et al., 2020). Hydroxychloroquine leads to inhibition of the inward rectifier K+ channels. This is associated with the prolongation of QTc (Kazama et al., 2012) . Docking studies suggest that this inhibition occurs due to the binding of nitrogen and quinoline ring present in hydroxychloroquine with the potassium channels J o u r n a l P r e -p r o o f (Rodríguez-Menchaca et al., 2008) . Studies suggest that chloroquine maximum dose of 1200 mg per day for 2-6 weeks would not lead to cardiac toxicity (Munster et al., 2002) . Based on this data as well as other Pharmacokinetics/Pharmacodynamics models used in the experiment, it is expected that hydroxychloroquine 400-600 mg twice a day for 10 days or less would not lead to cardiac toxicity in patients without any QTc prolongation risk (Tisdale et al., 2013) .

Hydroxychloroquine may lead to other toxicities like retinopathy and gastrointestinal toxicity but doses up to 1200 mg were well tolerated in patients with rheumatologic disease as well as cancer (Munster et al., 2002) . More randomized clinical trials and various Pharmacokinetics/Pharmacodynamics models are required to find the drug dosing regimens as well as toxicities and adverse drug reactions of various other repurposed drugs for Covid-19.

New molecules and new drugs need to be discovered with lesser side effects to combat Covid-19.

by the virus to generate various NSP required for the replication of the virus (ul Qamar et al., 2020; Anand et al., 2003) . The 3D structure of 3CL pro predicted by homology modeling consisted of 3 domains. The substrate-binding site that is situated between domains I and II has a Cys-His catalytic dyad. Based on earlier studies, a library of 32,297 antiviral natural compounds was screened against the homology model of SARS-CoV-2 3CL pro . The results helped to identify nine natural, non-toxic, druggable compounds that could bind to the catalytic dyad and receptor binding site of SARS-CoV-2 3CL pro (Table 1) . 5,7,3',4'-Tetrahydroxy-2'-(3,3-dimethylallyl) isoflavone, extracted from Psorothamnus arborescens showed a very high docking score with the highest binding affinity due to the formation of strong hydrogen bonds (Fig. 4) (ul Qamar et al., 2020) . The other screened phytochemicals displayed much closer interactions with catalytic dyad residues than other drugs proposed by drug repurposing studies that target SARS-CoV-2 3CL pro , like colistin, nelfinavir, and prulifloxacin, used as controls in the study ) (ul Qamar et al., 2020; Li et al., 2020) . Along with the isoflavone, two other phytochemical complexes, methyl rosmarinate extracted from Hyptis atrorubens, and myricitrin extracted from Myrica cerifera were very stable when subjected to molecular docking simulations (Fig. 4) . Hydrogen bonds responsible for stabilizing interactions between proteins also remained stable throughout. In the future, in-vivo and in-vitro analyses are needed for the transformation of the potential inhibitors into clinical drugs. This would help to develop novel, non-toxic, natural anti-Covid-19 drugs in the future ) (ul Qamar et al., 2020).

The recent spread of coronavirus SARS-CoV-2 has shown that clinical management and treatment of infected patients are lacking. Currently, the maximum mortality rate is due to respiratory failure from ARDS. The major clinical treatment consists of symptom management J o u r n a l P r e -p r o o f and oxygen therapy with mechanical ventilation for patients with respiratory failure. The convalescent plasma containing SARS-CoV-2-specific neutralizing antibodies has also been used to treat a small number of Covid-19 patients (Cao, 2020) . Recently it was reported that patients with severe Covid-19 exhibit cytokine storm syndrome. Therefore, identification (decreasing platelet counts or increasing ferritin) and treatment of hyperinflammation by drug repurposing using existing, approved therapies is recommended to reduce the rising mortality (Mehta et al., 2020) .

For identification and testing, the in vitro diagnostic assays for Covid-19 use real-time reverse transcriptase-polymerase chain reaction (RT-PCR) that generally takes a few h and are expensive. Cepheid, USA designed a Covid-19 test kit and reduced the assay duration to 45 min.

Abbott ID Now™ Covid-19 test is the point-of-care in vitro diagnostic assay that can detect SARS-CoV-2 in just 5 min. It uses the isothermal nucleic acid amplification technology to detect viral RNA from SARS-CoV-2 qualitatively. Immunoassays like enzyme-linked immunosorbent assay (ELISA), lateral flow immunoassay, and chemiluminescent immunoassay which help to detect immunoglobulin G (IgG) and immunoglobulin M (IgM) can also be used for Covid-19 diagnosis (Vashist, 2020) . SARS-CoV-2 DNA Endonuclease-Targeted CRISPR Trans Reporter (DETECTR) assay is a rapid (<40 min) CRISPR-Cas12-based lateral flow assay which is pending approval and is faster than the US Centers for Disease Control and Prevention SARS-CoV-2 real-time RT-PCR assay (Broughton et al., 2020) . The CovidNudge test is another sensitive and rapid point-of-care test that does not require laboratory handling or sample preprocessing. The nasopharyngeal swabs are inserted directly into a cartridge which contains the reagents required for RT-PCR reactions, including technical replicates of SARS-CoV-2 gene J o u r n a l P r e -p r o o f targets. The overall sensitivity of this test compared to the laboratory-based testing was 94% and the specificity was 100% (Gibani et al., 2020) .

For the treatment of Covid-19, although various studies suggest that chloroquine can be employed because it can inhibit SARS-CoV-2 infected kidney-derived cell-line Vero cells, a recent study reported that chloroquine could not block the SARS-CoV-2 infected TMPRSS2positive lung cell line Calu-3. This suggests that chloroquine does not target a lung cell viral activation pathway, and thus is unlikely to protect us against SARS-CoV-2 (Hoffmann et al., 2020; Haq et al., 2020) . Another study presented that hydroxychloroquine exhibited antiviral activity against the virus-infected kidney cells Vero E6 but when used against SARS-CoV-2 infection in non-human primates (macaques), neither hydroxychloroquine alone nor the combination therapy of azithromycin and hydroxychloroquine showed any significant effect as a prophylactic or therapeutic agent (Maisonnasse et al., 2020) . On 4 July 2020, WHO accepted the recommendation from the Solidarity Trial's International Steering Committee to discontinue the use of lopinavir/ritonavir and hydroxychloroquine arms for the trial because the interim results 

Covid-19 vaccines being developed around the world are mainly of two different forms; classical vaccine platforms which include live-attenuated viruses, whole-inactivated viruses, protein subunits, and virus-like particles; as well as next-generation vaccine platforms like viral DNA vaccines, RNA vaccines, viral vectors, and antigen-presenting cells (Fig. 5A ) (Van Riel and de Wit, 2020). Nanotechnology also benefits the modern vaccines because nanomaterials can mimic viral structures, act as adjuvants and are ideal for targeted antigen delivery (Shin et al., 2020) .

New techniques like immunoinformatics to identify potential vaccine candidates or a prefusion version of viral protein have been beneficial for Covid-19 vaccine research (Dance, 2020) .

However, the prefusion SARS-CoV-2 S has some stability issues which can be covalently stabilized by an intermolecular disulfide bond in a closed conformation to enhance SARS-CoV-2 S resistance to proteolysis and thus, it can be used in vaccine design, serology, and immunology India (DCGI) for phase III human clinical trials and has emergency use authorization in India. It is a whole-virion inactivated vaccine which means it cannot replicate in humans but will trigger an antibody response (Available at who.int; Available at nytimes.com). Among these, Comirnaty or BNT162 which is a RNA-based vaccine with 3 lipid nanoparticle platform-mRNAs developed by Pfizer and BioNTech, was the first Covid-19 vaccine to receive emergency use authorization in the US by the FDA. It is approved for use in many countries like Canada, Switzerland and Bahrain (Available at who.int; Available at nytimes.com).

In the future, research has to be carried out in different parts of the world using various in vitro, in vivo, and in silico models to study viral replication and pathogenesis. UV-C light of 200-230 nm wavelength can be used to limit virus transmission in indoor spaces .

Various imaging and molecular diagnostic tools like atomic-force microscopy, fluorescence microscopy, electron microscopy, and other computational biology tools can be used to study SARS-CoV-2 efficiently and treat Covid-19 (Kaniyala Melanthota et al., 2020) .

The emergence of SARS-CoV-2 from China in December 2019 led to the Covid-19 pandemic which has affected millions of people all over the world. This disease leads to pneumonia and ARDS which may progress to multi-organ failure and ultimately death. Various studies identified the PPIs between the ORFs and NSPs of SARS-CoV-2 and human proteins, the viral proteases which can be targeted, and other novel viral targets using AP-MS, cheminformatic analyses, and indirect immunofluorescence assays. These viral proteins and their interactions could help us to understand the effect of SARS-CoV-2 on human cellular metabolism as well as to identify and formulate various drugs and vaccines to combat Covid-19. Various in silico J o u r n a l P r e -p r o o f studies on cheminformatics software, in vitro studies on lung and kidney cell lines, and in vivo studies in model organisms and humans were performed to test the efficiency of various repurposed drugs and their combination therapies. Toxicity testing was also done for the repurposed drugs identified to find out the adverse drug reactions as well as to formulate the drug dosage regimens of the drugs and their different combinations. Due to cardiac toxicities and QTc prolongation caused due to a few repurposed drugs, a library of new molecules like anti-viral phytochemicals was screened against the homology model of SARS-CoV-2 3CL pro by molecular docking simulations. The availability of these prophylactic and therapeutic drugs and their safety is of great concern for the treatment of Covid-19. Randomized controlled trials are necessary to test the efficacy and safety of the drugs identified by in silico and in vitro studies. Inadequate knowledge about the true number of affected individuals in developing countries due to Covid-19 tests being done only on individuals with strong symptoms is another major concern. Time-efficient and cost-effective Covid-19 diagnostic assays like in vitro diagnostic assays using RT-PCR and immunoassays need to be developed and used worldwide to fight the pandemic. Newer diagnostic methods, novel anti-viral drug research, classical and next-generation vaccines being developed around the world are the only ways to combat Covid-19. Newer techniques like immunoinformatics will be helpful to identify potential vaccine candidates and we shall be able to combat the pandemic in a much better and efficient way in the future. The large-scale and efficient production of vaccines, the duration of antibody response to the vaccine, as well as lack of masks, gloves, and ventilators in the underdeveloped and developing countries, is another major concern which the scientific and the medical community has to face. However, a thorough understanding of the current situation and particles scattered in the vesicle (V)-rich area in the cytoplasm. q) Virus particle released from the ciliated cells by exocytosis (arrow). r) SARS-CoV-2 particle with distinctive and clear spikes (arrow), without spikes (empty arrow) and with partial spikes (triangle). The figure is adapted from reference (Zhu et al., 2020) . 

COVID-19 therapies and vaccine landscape

COVID-19 VACCINES GET BIOTECH BOOST

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

Details -Public Health Image Library (PHIL)

Draft landscape of COVID-19 candidate vaccines. World Health Organization

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin

VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

5-(5, 6-Dichloro-2-indolyl)-2-methoxy-2, 4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity

Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Back to normal: an old physics route to reduce SARS-CoV-2 transmission in indoor spaces

Optimizing hydroxychloroquine dosing for patients with COVID-19: an integrative modeling approach for effective drug repurposing

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study

Azithromycin induces anti-viral responses in bronchial epithelial cells

Electron microscopy of SARS-CoV-2: a challenging task. The Lancet

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

2020. A SARS-CoV-2-Human Protein-Protein Interaction

Antimalarials-are they effective and safe in rheumatic diseases

Artemisia annua: Trials are needed for COVID-19

Rat liver and kidney contain high densities of σ1 and σ2 receptors: characterization by ligand binding and photoaffinity labelling

Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2

Insights from nanomedicine into chloroquine efficacy against COVID-19

Treating COVID-19 with chloroquine

Stress granules and processing bodies in translational control

Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease

Elucidating the microscopic and computational techniques to study the structure and pathology of SARS-CoVs

Voltage-dependent biphasic effects of chloroquine on delayed rectifier K+-channel currents in murine thymocytes

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19

Perioperative glycemic management in 2011: paradigm shifts

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation

Candidate drugs against SARS-CoV-2 and COVID-19

Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones

COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet

Middle East respiratory syndrome coronavirus (MERS-CoV). World Health Organization

MERS-CoV papain-like protease has deISGylating and deubiquitinating activities

CALM regulates clathrincoated vesicle size and maturation by directly sensing and driving membrane curvature

Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step

Sigma-1Rs are upregulated via PERK/eIF2α/ATF4 pathway and execute in ER stress

Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus

Cardiovascular risks with azithromycin and other antibacterial drugs

Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona-and picornaviruses

Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis

Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model

Azithromycin in viral infections

Discovery and SAR of 5-(3-chlorophenylamino) benzo [c][2, 6] naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer

Recent discovery and development of inhibitors targeting coronaviruses

Mouse hepatitis coronavirus replication induces host translational shutoff and mRNA decay, with concomitant formation of stress granules and processing bodies

SARS-CoV-2 and coronavirus disease 2019: what we know so far

Casein kinase 2 is linked to stress granule dynamics through phosphorylation of the stress granule nucleating protein G3BP1

Antiinflammatory action of glucocorticoids-new mechanisms for old drugs

Considerations for drug interactions on QTc in exploratory COVID-19 treatment

The molecular basis of chloroquine block of the inward rectifier Kir2. 1 channel

SINTBAD, a novel component of innate antiviral immunity, shares a TBK1-binding domain with NAP1 and TANK

Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing

Simplification of antiretroviral treatment from darunavir/ritonavir monotherapy to darunavir/cobicistat monotherapy: effectiveness and safety in routine clinical practice

High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses

COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses

Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface

Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors

Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro

COVID-19 vaccine development and a potential nanomaterial path forward

The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors

Solidarity" clinical trial for COVID-19 treatments. World Health Organization

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). World Health Organization

Cytokine storm in COVID-19: the current evidence and treatment strategies

Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol

Development and validation of a risk score to predict QT interval hospitalized patients

Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages

Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants

High-dose chloroquine for uncomplicated plasmodium falciparum malaria is well tolerated and causes similar QT interval prolongation as standard-dose chloroquine in children

Next-generation vaccine platforms for COVID-19

In vitro diagnostic assays for COVID-19: recent advances and emerging trends

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

COVID-19) Dashboard. World Health Organization

Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication

A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery

SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects

NLRX1 negatively regulates TLR-induced NF-κB targeting TRAF6 and IKK

NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2

pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN

Electrophysiologic studies on the risks and potential mechanism underlying the proarrhythmic nature of azithromycin

COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression

Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells

We thank the Department of Science and Technology ( 

The authors declare no conflict of interest.J o u r n a l P r e -p r o o f